Median Technologies Boosts Cash Position and Expands eyonis® LCS Commercialization — Median Technologies SA

Event summary

Median Technologies completed a €50 million capital increase, extending its cash runway into early 2028.
iCRO business reported a 4.4% year-over-year revenue increase and a record backlog of €82.4 million as of June 30, 2026.
eyonis® LCS received FDA clearance in the U.S. and CE marking in Europe, enabling commercial launches in both regions.

The big picture

Median Technologies is transitioning from a services-focused model to a hybrid approach, combining its profitable iCRO business with the commercial rollout of AI-powered diagnostic tools. The strategic shift positions Median at the forefront of AI-driven early cancer diagnosis, capitalizing on favorable regulatory environments and expanding market access. With a strengthened cash position and record backlog, the company is well-positioned to execute its growth strategy, though success will hinge on sustained demand from biopharmaceutical clients and effective commercialization of eyonis® LCS.

What we're watching

Commercial Execution: How Median will scale eyonis® LCS adoption in the U.S. and Europe, leveraging its regulatory approvals.
Portfolio Expansion: Whether Median can successfully develop new indications for the eyonis® portfolio beyond lung cancer screening.
Financial Sustainability: The pace at which iCRO business growth will support long-term financial health amid eyonis® commercialization costs.